PSD Bank Westfalen-Lippe eG

Suchergebnis - CENTESSA PHARMACEUTICALS PLC NAM.-AKT.(SP.ADRS)/1 O.N.

Zeit	Titel
13.09 04:34	dpa-AFX: GNW-Adhoc: Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
11.09 22:04	dpa-AFX: GNW-Adhoc: Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
10.09 13:00	dpa-AFX: GNW-Adhoc: Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
27.08 14:00	dpa-AFX: GNW-Adhoc: Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
13.08 13:00	dpa-AFX: GNW-Adhoc: Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024
13.05 22:10	dpa-AFX: GNW-Adhoc: Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
24.04 03:36	dpa-AFX: GNW-Adhoc: Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
23.04 22:17	dpa-AFX: GNW-Adhoc: Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
22.04 13:00	dpa-AFX: GNW-Adhoc: Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
28.03 21:28	dpa-AFX: GNW-Adhoc: Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
10.12 18:05	dpa-AFX: GNW-Adhoc: Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia
13.11 22:05	dpa-AFX: GNW-Adhoc: Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
25.10 14:00	dpa-AFX: GNW-Adhoc: Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750's Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders